on providing unique biodegradable implants with sustained drug delivery to improve patient outcomes and quality of life for patients suffering from ophthalmic diseases such as glaucoma.
The versatile Prezia Sustained Drug Delivery Technology platform is based on extensive scientific research that has resulted in the creation of a unique method for precise and controlled drug delivery.
PolyActiva has showcased their Phase 2 clinical data for their lead candidate PA5108 Ocular Implant in glaucoma patients.
Patients received continuous therapy for intraocular pressure (IOP) for over 48 weeks, receiving their first and second implants at week 0 and 21 respectively. Clinically meaningful IOP reductions of 26-35% were observed over the 48-week treatment period, and 94% of patients did not require additional drop therapy.
PolyActiva has recently been awarded a $1.5m CUREator Grant, which will be used to progress its second generation ocular implant as a treatment for patients with glaucoma, targeting sustained daily dosing for 12 months.
If you are interested in getting in touch with PolyActiva and wish to connect, please complete the form below:
© 2025 PolyActiva. All Rights Reserved. Caution: PolyActiva products are not for sale in the US